SCHEMBL23577907

SCHEMBL23577907

CCOC1(c2ccc(C(=O)N3CCC(c4cccc(C(F)(F)F)c4)CC3)cc2)COC1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ DRD2 P14416 1/20 0.46
▸ CCR2 P41597 1/20 0.45
▸ RBP4 P02753 1/20 0.44
▸ UBE2M P61081 2/20 0.43
▸ DCUN1D1 Q96GG9 2/20 0.43
▸ PARP10 Q53GL7 1/20 0.42
▸ HSD11B1 P28845 1/20 0.42
▸ USP5 P45974 1/20 0.42
▸ MGLL Q99685 1/20 0.41
▸ CHRM4 P08173 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ CACNA1B Q00975 1/20 0.40
▸ MAPK7 Q13164 1/20 0.40
▸ ESR1 P03372 1/20 0.40
▸ ESR2 Q92731 1/20 0.40
▸ CNR1 P21554 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23577373 0.90 UBE2M (0.47) DRD2CCR2RBP4UBE2MDCUN1D1
SCHEMBL23605549 0.89 DRD2 (0.46) DRD2CCR2RBP4USP5CHRM4
SCHEMBL23577508 0.89 GAA (0.46) PARP10HSD11B1MGLLMAPK7CNR1
SCHEMBL23577528 0.85 EPHX2 (0.41) RBP4PARP10
SCHEMBL23578349 0.84 RBP4 (0.49) DRD2CCR2RBP4UBE2MDCUN1D1
SCHEMBL23578389 0.81 RBP4 (0.47) RBP4
SCHEMBL23605175 0.79 PROKR1 (0.51) —
SCHEMBL23577488 0.79 EGLN1 (0.47) PARP10HSD11B1MGLLMAPK7CNR1
SCHEMBL23577378 0.79 GAA (0.45) PARP10HSD11B1MGLLMAPK7CNR1
SCHEMBL23577339 0.78 MAPK7 (0.48) PARP10HSD11B1MGLLMAPK7CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4081509-A1 NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA Zydus Lifesciences Limited (IN) 2022-11-02 — — EP claimed
CN-114901640-A Novel compounds useful for the treatment of dyslipidemia 兹杜斯生命科学有限公司 2022-08-12 — — CN claimed
EP-4081509-A1 NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA Zydus Lifesciences Limited (IN) 2022-11-02 — — EP disclosed
CN-114901640-A Novel compounds useful for the treatment of dyslipidemia 兹杜斯生命科学有限公司 2022-08-12 — — CN disclosed
WO-2021130723-A1 NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA CADILA HEALTHCARE LIMITED (IN) 2021-07-01 — — WO disclosed
Send feedback